Who are Dinoprostone vaginal pessary's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propess® (dinoprostone), Latanoprost RATIOPHARM© latanoprost eyedrops.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dinoprostone-vaginal-pessary.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dinoprostone vaginal pessary — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dinoprostone vaginal pessary (Dinoprostone vaginal pessary) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F2α analog. Area: Obstetrics.

marketed Prostaglandin F2α analog Prostaglandin F (FP) receptor Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

Dinoprostone vaginal pessary (Dinoprostone vaginal pessary) — Università degli Studi di Brescia. Dinoprostone is a prostaglandin F2α analog that binds to prostaglandin receptors on the uterus to stimulate myometrial contractions and promote cervical ripening and labor induction.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dinoprostone vaginal pessary TARGET	Dinoprostone vaginal pessary	Università degli Studi di Brescia	marketed	Prostaglandin F2α analog	Prostaglandin F (FP) receptor
Propess® (dinoprostone)	Propess® (dinoprostone)	University Hospital, Clermont-Ferrand	marketed	Prostaglandin F2α analog	Prostaglandin F receptor (FP receptor)
Latanoprost RATIOPHARM© latanoprost eyedrops	Latanoprost RATIOPHARM© latanoprost eyedrops	University of Catanzaro	marketed	Prostaglandin F2α analog	Prostaglandin F (FP) receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F2α analog class)

University Hospital, Clermont-Ferrand · 1 drug in this class
University of Catanzaro · 1 drug in this class
Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dinoprostone vaginal pessary — Competitive Intelligence Brief. https://druglandscape.com/ci/dinoprostone-vaginal-pessary. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab